ECSS
REGN icon

Eurizon Capital SGR SpA’s Regeneron Pharmaceuticals REGN Stock Holding History

Eurizon Capital SGR SpA’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.66M Sell
15,467
-1,058
-6% -$720K 0.03% 335
2026
Q1 		$12.7M Buy
16,525
+2,960
+22% +$2.27M 0.04% 295
2025
Q4 		$10.5M Buy
+13,565
New +$9.21M 0.03% 283

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Eurizon Capital SGR SpA's REGN Position: Q2 2026 in Review

Eurizon Capital SGR SpA reduced its Regeneron Pharmaceuticals (REGN) stake by 6.4% in Q2 2026, selling an estimated $720K and leaving 15,467 shares worth $9.66M. The position accounts for 0.03% of the portfolio, ranked #335.

Eurizon Capital SGR SpA first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.7M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Eurizon Capital SGR SpA held 15,467 shares of Regeneron Pharmaceuticals worth $9.66M as of Q2 2026.
  • Eurizon Capital SGR SpA sold 1,058 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $720K.
  • Regeneron Pharmaceuticals made up 0.03% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #335 holding.
  • Eurizon Capital SGR SpA first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Eurizon Capital SGR SpA's Regeneron Pharmaceuticals position peaked at $12.7M in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.